These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19568715)

  • 61. [Shen warming Pi strengthening method intervened IBS-D rats: an efficacy assessment].
    Su XL; Tang YP; Zhang J; Bai YB; Shi HX; Liu YJ; Chang YJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Feb; 34(2):197-202. PubMed ID: 24672945
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Effect of TCM therapy for invigorating Pi, soothing Gan, eliminating dampness and resolving blood stasis on the short-term quality of life in patients with diarrhea type irritable bowel syndrome].
    Wu B; Zhang SS
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Oct; 28(10):894-6. PubMed ID: 19123325
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Effect of Fagopyrum cymosum (Trev.) Meisn alcohol extract on defecation and isolated colon of diarrhea-IBS rats and its mechanism].
    Liu LN; Yan J; Sun ZG
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Dec; 34(12):1469-75. PubMed ID: 25632748
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
    Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
    Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
    Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
    Chen C; Tao C; Liu Z; Lu M; Pan Q; Zheng L; Li Q; Song Z; Fichna J
    Phytother Res; 2015 Nov; 29(11):1822-7. PubMed ID: 26400188
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial.
    Plasse TF; Barton G; Davidson E; Abramson D; Kalfus I; Fathi R; Raday G; Harris MS
    Am J Gastroenterol; 2020 Sep; 115(9):1466-1473. PubMed ID: 32639235
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.
    Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Brain regions involved in moxibustion-induced analgesia in irritable bowel syndrome with diarrhea: a functional magnetic resonance imaging study.
    Zhu Y; Wu Z; Ma X; Liu H; Bao C; Yang L; Cui Y; Zhou C; Wang X; Wang Y; Zhang Z; Zhang H; Jia H; Wu H
    BMC Complement Altern Med; 2014 Dec; 14():500. PubMed ID: 25516481
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
    Mangel AW; Chaturvedi P
    Digestion; 2008; 78(4):180-6. PubMed ID: 19092244
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of Peppermint oil in diarrhea predominant IBS - a double blind randomized placebo - controlled study.
    Alam MS; Roy PK; Miah AR; Mollick SH; Khan MR; Mahmud MC; Khatun S
    Mymensingh Med J; 2013 Jan; 22(1):27-30. PubMed ID: 23416804
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
    Brenner DM; Sayuk GS
    Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells.
    Vivinus-Nébot M; Dainese R; Anty R; Saint-Paul MC; Nano JL; Gonthier N; Marjoux S; Frin-Mathy G; Bernard G; Hébuterne X; Tran A; Theodorou V; Piche T
    Am J Gastroenterol; 2012 Jan; 107(1):75-81. PubMed ID: 21931380
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Therapeutic effect of herb-separated moxibustion at Jinsuo (GV 8)-eight-diagram points on diarrhea-type irritable bowel syndrome of liver stagnation and spleen deficiency].
    Hao LJ; Shi ZM
    Zhongguo Zhen Jiu; 2020 Jul; 40(7):702-6. PubMed ID: 32648391
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nerve growth factor and diarrhea-predominant irritable bowel syndrome (IBS-D): a potential therapeutic target?
    Xu XJ; Liu L; Yao SK
    J Zhejiang Univ Sci B; 2016 Jan; 17(1):1-9. PubMed ID: 26739521
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
    Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
    Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.
    Brenner DM; Sayuk GS; Gutman CR; Jo E; Elmes SJR; Liu LWC; Cash BD
    Am J Gastroenterol; 2019 Sep; 114(9):1502-1511. PubMed ID: 31356229
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome.
    Zielińska M; Chen C; Mokrowiecka A; Cygankiewicz AI; Zakrzewski PK; Sałaga M; Małecka-Panas E; Wlaź P; Krajewska WM; Fichna J
    J Pharm Pharmacol; 2015 Feb; 67(2):244-54. PubMed ID: 25515402
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of TongXie-YaoFang on Cl(-) and HCO3 (-) Transport in Diarrhea-Predominant Irritable Bowel Syndrome Rats.
    Lu X; Zhang S; Yang C; Wang Z; Zhao L; Wu Z; Xie J
    Evid Based Complement Alternat Med; 2016; 2016():7954982. PubMed ID: 27403199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.